![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 38, 26705-26712, September 17, 1999
§,
§
From the
Department of Environmental Biology,
Graduate School of Agricultural Science, Tohoku University, Sendai
981-8555, Japan and the ¶ Department of Biochemistry, Institute of
Development, Aging and Cancer, Tohoku University,
Sendai 980-8575, Japan
| |
ABSTRACT |
|---|
|
|
|---|
During activation of platelets by thrombin
phosphorylation of Thr558 in the C-terminal domain of
the membrane-F-actin linking protein moesin increases transiently, and
this correlates with protrusion of filopodial structures. Calyculin A
enhances phosphorylation of moesin by inhibition of phosphatases. To
measure this moesin-specific activity, a nonradioactive enzyme-linked
immunosorbent assay method was developed with the synthetic peptide
Cys-Lys555-Tyr-Lys-Thr(P)-Leu-Arg560
coupled to bovine serum albumin as the substrate and moesin
phosphorylation state-specific polyclonal antibodies for the detection
and quantitation of dephosphorylation. Calyculin A-sensitive and
-insensitive protein-threonine phosphatase activities were detected in
platelet lysates and separated by DEAE-cellulose chromatography. The
calyculin A-sensitive enzyme was identified as a type 1 protein
phosphatase. The calyculin A-insensitive enzyme activity was purified
to homogeneity by phenyl- Sepharose, protamine-, and phosphonic acid
peptide-agarose chromatography and characterized biochemically and
immunologically as a 53-kDa protein(s) and a type 2C protein
phosphatase (PP2C). Phosphorylation of Thr558 is necessary
for F-actin binding of moesin in vitro. The purified enzyme, as well as bacterially made PP2C Members of the moesin protein family are localized membrane
structures rich in actin filaments such as filopodia, membrane ruffles,
microvilli, or the cleavage furrow in a wide range of cell types
(1-3). They are proposed to act as linkers between the plasma membrane
and the actin cytoskeleton. The N-terminal domain binds
phosphoinositides (4), CD43 (5), CD44 (6), intercellular adhesion
molecules (ICAM-1, -2, and -3 (7-9), Rho GDI (10), EBP-50 (11), type
II protein kinase A regulatory subunit (12), myosin-binding subunit
(13), Nhe-Rf (14), and Dbl (15), whereas the C-terminal domain
interacts with F-actin (16). These interactions are thought to be
dynamically regulated by signaling molecules. One of the candidate
molecules is phosphatidylinositol 4,5-bisphosphate, which appears to be
necessary for stabilizing moesin-CD44 interaction (4, 6). Moesin is
phosphorylated in human platelets by thrombin activation at a single
site, Thr558, that is located within or near the F-actin
binding domain in the C-terminal region of the moesin sequence (17).
This region is nearly identical for all moesin-like proteins, and
experiments in other cell types identified Thr558 as a
common phosphorylation site as well (18, 19).
Thrombin stimulation of human platelets induces a rapid but transient
increase in phosphorylation that correlates with F-actin binding
activity of moesin (18). Although several phosphokinase and phosphatase
inhibitors, including some acting on enzymes specific for modifying
tyrosine residues, modulated phosphorylation at the Thr558
site, regulatory mechanisms of moesin phosphorylation are not well
understood. Rho-dependent kinase phosphorylates two
threonine residues of a C-terminal fragment of the homologous protein
radixin in vitro, but the enzyme did not phosphorylate the
full-length protein or did so rather poorly (19). Protein kinase C Matsui et al. (19) have shown that phosphorylation of
Thr558 in the C-terminal fragment of radixin inhibited the
interaction of the fragment with the N-terminal fragment. This
modification had no effect on the constitutive F-actin binding activity
of the C-terminal fragment. More recent evidence strongly suggests that
phosphorylation and other factors in the full-length protein disrupt
structural features in vitro under certain conditions, causing a substantial conformational change that exposes the high affinity binding site for F-actin (20, 21). Dephosphorylation of the
modified protein would be expected to reverse this allosteric change
and to lead to inactivation of this binding site.
The present work demonstrates that calyculin A-sensitive and
-insensitive phosphatases are detectable in human platelet lysates with
a newly developed assay with a moesin-specific substrate. The calyculin
A-insensitive enzyme was purified and identified as a type 2C protein
phosphatase. The purified enzyme efficiently dephosphorylates highly
purified in vivo phosphorylated platelet moesin and
inactivates F-actin binding. This result lends support to previous
speculation that phosphorylation and dephosphorylation regulate F-actin
binding of full-length endogenous moesin by an allosteric mechanism
(19, 22).
Materials
Affinity purified polyclonal antibodies pAbMo (95/2)
were used for the identification and immunoprecipitation of moesin. The
mouse monoclonal antibody mAbMo (38/87) was kindly provided by R. Schwartz-Albiez and H. Furthmayr and was used for detection of moesin.
The affinity purified polyclonal antibodies pAbKYKpTLR (affinity purified polyclonal antibodies specific for phosphorylated moesin) and pAbKYKTLR were prepared as described previously (18). Rabbit polyclonal protein phosphatase type 1 (PP1)1 antibodies (FL-18),
which reacts with catalytic subunits of PP1, PP2A, PP2B and PPX and
mouse monoclonal PP1 antibodies (E-9) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Recombinant rat PP2C Preparation of Substrates
Phosphorylated moesin (phospho-moesin) was isolated from human
platelets treated with calyculin A, and
Cys-Lys555-Tyr-Lys-Thr(P)-Leu-Arg560
(KYKpTLR)-coupled bovine serum albumin (BSA) was prepared as
described previously (18). para-Nitrophenylphosphate was purchased from Sigma.
Preparation of Affinity Columns
The KYKcpTLR-agarose (where cpT indicates
Isolation of Subcellular Fractionation of Human Platelets
Outdated platelets were provided as platelet-rich plasma by the
Miyagi Red Cross Blood Center (Japan). Gel-filtered platelets (17) were
centrifuged at 800 × g for 15 min at 30 °C and
resuspended in extraction buffer (50 mM Tris-HCl, 0.5 mM EGTA, 50 mM benzamidine, 10 µg/ml
aprotinin, 10 µM E-64, 100 µM
p-amidinophenylmethanesulfonyl fluoride, and 100 µM leupeptin, pH 7.4). The platelets were quickly homogenized using a Dounce homogenizer and subsequently subjected to an
ultracentrifugation at 100,000 × g for 1 h at
4 °C. This first supernatant is referred to as the "cytosol."
The pellet was rehomogenized using 1 × Triton X-100 lysis buffer
(1% Triton X-100, 50 mM Tris-HCl, 0.1 mM
2-mercaptoethanol, 10 µg/ml aprotinin, 10 µM E-64, 100 µM p-amidinophenylmethanesulfonyl fluoride,
and 100 µM leupeptin, pH 7.4) and again centrifuged at
15,600 × g at 4 °C for 4 min. This second
supernatant is referred to as the "membrane fraction."
For other experiments, gel-filtered platelets were resuspended in 100 µl of Tyrode's buffer (136 mM NaCl, 2.9 mM
KCl, 12 mM NaHCO3, 0.36 mM
NaH2PO4, 1.8 mM CaCl2,
0.4 mM MgCl2, 5.5 mM glucose, pH
7.4) at 1 × 109 platelets/ml. Platelets were
activated by the addition of 1.0 National Institutes of Health unit of
thrombin/ml at 37 °C or incubated for 10 min with 100 nM
calyculin A or 1 µM staurosporine at 37 °C. Platelets
were lysed by addition of an equal volume of 2 × Triton X-100
lysis buffer. The lysates were immediately centrifuged at 15,600 × g at 4 °C for 4 min to sediment cytoplasmic actin
filaments. This supernatant is referred to as the "Triton X-100
extract." The pellet was resuspended in 200 µl of 1× Triton X-100
lysis buffer containing 500 mM NaCl, homogenized, and again centrifuged at 15,600 × g at 4 °C for 4 min. The
supernatant of this step is referred to as the "NaCl extract."
Phosphatase Assay
To monitor purification of phosphatase, BSA-KYKpTLR
was used as a substrate in the enzyme assays. Microtiter plate wells
were coated overnight at room temperature with 100 µl of peptide
solution (10 mg of peptide, KYKpTLR, as BSA conjugate/ml in
10 mM Tris-HCl, pH 8.5, 100 mM NaCl, 0.02%
sodium azide). After coating, wells were washed three times with TTBS
(20 mM Tris-HCl, pH 7.6, 136 mM NaCl, 0.05%
Tween 20), blocked for 1 h with TTBS containing 5% nonfat milk,
and washed again with TTBS. After addition of 90 µl of buffer A (20 mM Tris-HCl, pH 7.2, 0.1 mM EDTA, 0.1% The specific phosphatase activity was calculated with purified
phospho-moesin as the substrate as follows. The standard reaction mixture of phosphatase assay contained buffer B (10 mM
Tris-HCl, pH 7.2, 0.1 mM EDTA, 0.1% Protein Assay
Protein concentrations were determined with the bicinchoninic
acid protein assay reagent (Pierce) with BSA as a standard. Because of
limits of sensitivity and interference by Purification of Moesin Phosphatase
Outdated platelets were washed as previously described (26) and
lysed with 1× Triton X-100 lysis buffer. After centrifugation at
25,000 × g for 30 min at 4 °C, the supernatant was
subjected to successive chromatographic steps of purification either
directly or after ethanol treatment (27). All purification procedures were performed at 4 °C. At each step, phosphatase activity was measured by the ELISA procedure.
DEAE-Cellulose Chromatography--
The sample was loaded onto a
DEAE-cellulose column (15.6 × 320 mm), pre-equilibrated with
buffer C (10 mM Tris-HCl, pH 7.2, 0.1 mM EDTA,
0.1% Phenyl-Sepharose HP Chromatography--
Phenyl-Sepharose HP
column (15 × 57 mm) was washed with ethanol, followed by buffer C
containing 1 M NaCl. After loading the sample from step 1, the column was eluted at a flow rate of 1 ml/min with a linear salt
gradient (150 ml) from 1 to 0 M NaCl in the equilibrating
buffer. The phosphatase fractions were pooled.
Protamine-Agarose Chromatography--
The pooled fractions from
the previous step were loaded onto a protamine-agarose column (10 × 13 mm), equilibrated with Buffer C. The phosphatase was eluted with
a linear salt gradient (40 ml) from 0 to 1 M NaCl in the
equilibrating buffer at a flow rate of 0.5 ml/min. Fractions containing
phosphatase were pooled and diluted 1:4 with 10 mM
Tris-HCl, pH 7.2.
KYKcpTLR-Agarose Affinity Chromatography--
The
diluted sample from the previous step were loaded onto a
KYKcpTLR affinity column (10 × 13 mm) equilibrated
with 10 mM Tris-HCl, pH 7.2. Phosphatase was eluted with a
linear salt gradient (24 ml) from 0 to 0.5 M NaCl in the
equilibrating buffer at a flow rate of 0.3 ml/min. Fractions containing
phosphatase were pooled.
The highly purified preparations were stored at 4 °C until they were
used. For longer storage, the enzyme was stored in buffer C containing
20% glycerol at Fast Protein Liquid Chromatography Gel Filtration
Chromatography
An aliquot of the purified phosphatase was concentrated in a
ultrafree centrifugal filter device (Millipore) and chromatographed on
a Superose 12 column (HR 10/30) equilibrated at 4 °C with 10 mM Tris, pH 7.4, 150 mM NaCl, 0.2 mM EDTA, 1 mM dithiothreitol, 5 mM
MgCl2, and 10% glycerol, at a flow rate of 0.4 ml/min. The volume at which standard proteins eluted from the column was determined in separate runs.
F-actin Co-sedimentation Assay
Phosphorylated moesin (0.3 µM) was incubated with
phosphatase in buffer B. After various periods of time, the mixture was incubated with phalloidin-stabilized F-actin in buffer F (10 mM Tris-HCl, pH 7.2, 0.5 mM Na2ATP,
5 mM MgCl2, 140 mM KCl, 0.2 mM dithiothreitol, 0.2 mM CaCl2,
0.1% dodecyl trimethyl ammonium chloride) for 30 min at 25 °C (20).
The filaments were then sedimented by centrifugation at 100,000 × g for 20 min at 25 °C. Proteins in the supernatants were
precipitated with trichloroacetic acid containing 2 mg/ml sodium
deoxycholate, and the precipitates were washed with ice-cold acetone.
Samples were then solubilized in SDS gel sample buffer and subjected to
SDS-PAGE. Moesin and phosphorylated moesin were detected by immunoblotting.
Alkaline or Acid Phosphatase Treatment
Purified phospho-moesin was treated with alkaline phosphatase
from calf intestine or Escherichia coli (Takara, Japan) (19) or wheat germ acid phosphatase (Nacalai Tesque, Kyoto, Japan) (28) as
described previously. The dephosphorylation was detected by Western
blotting probed with pAbKYKpTLR.
Detection of Protein-threonine Phosphatase Activity in Human
Platelets--
Originally, dephosphorylation of moesin was observed
after lysis of 32P-labeled platelets in the absence of
phosphatase inhibitors, suggesting the presence of a moesin phosphatase
(17). To study this further, we developed two nonradioactive methods,
an ELISA and an in vitro dephosphorylation assay. Both
assays are based on an antibody reagent that specifically recognizes
the phosphorylation state of moesin. The ELISA was performed with
BSA-KYKpTLR as the substrate. The substrate constitutes a
hexapeptide centered around the phosphorylation site of moesin. This
substrate can be dephosphorylated by addition of platelet lysates, and
dephosphorylation is detected with specific antibodies (Fig.
1A). To confirm that this
assay is measuring phosphatase and not protease activity, which might
have removed the phosphopeptide, we tested with antibodies that
specifically recognize the dephosphorylated peptide (18). As shown in
Fig. 1B, pAbKYKTLR reacted with BSA-KYKpTLR after
this substrate was incubated with cell lysate, indicating dephosphorylation rather than proteolytic modification. This was also
substantiated by the unchanged reactivity of the antibodies with
BSA-KYKpTLR when incubated with the cell lysate in the
presence of the protein phosphatase inhibitor calyculin A (Fig.
1A, lane 4). Because ELISA is simple and
time-saving, we used this method to monitor phosphatase activity during
purification. Both antibodies can be used for ELISA; however, the
pAbKYKpTLR reagent is more sensitive and specific than
pAbKYKTLR (Fig. 1 and Ref. 18). We therefore primarily used
pAbKYKpTLR. To make sure that KYKpTLR phosphatase
dephosphorylates full-length phospho-moesin, an in vitro
dephosphorylation assay was also carried out using highly purified
platelet phospho-moesin as the substrate, followed by Western blotting
with pAbKYKpTLR. This method allows to determine specific
phosphatase activity, because the amount of moesin and phospho-moesin
can be quantitated by Western blotting using pAbMo (95/2) or
mAbMo (38/87) and pAbKYKpTLR, respectively.
Two Distinct Phosphatase Activities Are Present in Human Platelet
Lysates--
We have previously shown that the addition of calyculin A
to human platelets caused a substantial increase in the number of phosphorylated moesin molecules (17). This large increase is explained
by inhibition of all phosphatase activity in the platelet lysate.
However, some phosphatase activity was detectable when 10 mM MgCl2 was added together with calyculin A
(Fig. 2A). This suggested that
distinct calyculin A-sensitive and -insensitive phosphatases existed in
the human platelets lysate. The contribution of each phosphatase
activity for the dephosphorylation of KYKpTLR peptide is
about 1:1 in this assay (Fig. 2A). This result is
inconsistent with our previous observations that preincubation of human
platelets with calyculin A for 10 min induced phosphorylation of all or nearly all moesin molecules (17). We examined whether addition of
calyculin A and/or MgCl2 before lysis affected the
calyculin A-insensitive phosphatase activity, but MgCl2
made no significant difference (Fig. 2B).
Distribution of Calyculin A-sensitive and -insensitive Phosphatase
Activity in Triton X-100 Fractions--
Cytosol and membrane fractions
were prepared from human platelets (29), and the associated phosphatase
activity was measured by the ELISA procedure. About 65% of the total
phosphatase activity was recovered in the Triton X-100 soluble membrane
fraction, whereas about 35% was in the soluble cytosolic fraction
(Fig. 3A). The calyculin
A-insensitive phosphatase activity preferentially fractionated with the
Triton X-100 soluble membrane material (compare bars 3 and
4 in Fig. 3A), whereas the calyculin A-sensitive
activity was almost equally distributed in the two fractions
(bars 2 minus 1 versus bars 4 minus 3 in Fig. 3A). Thrombin activation did not change this
distribution, and phosphatase activity was not contained in the Triton
X-100 insoluble fraction either before or after thrombin activation of
human platelets (Fig. 3B).
Purification of Protein-threonine Phosphatase from Human
Platelets--
The extraction studies established the Triton
X-100-solubilized preparation of resting human platelets as the optimal
starting material for purification of calyculin A-insensitive
phosphatases. The Triton X-100 extract was treated with ethanol, and
this treatment was necessary to remove contaminants prior to
chromatographic steps. The ethanol-treated sample was solubilized in
buffer C and passed through the DE52 column, which resolved two peaks
of phosphatase activity. Phosphatase activity was detected in fractions eluted with an NaCl gradient at ionic strengths corresponding to
110-200 mM NaCl (Fig. 4).
Addition of 100 nM calyculin A during ELISA inhibited part
of the activity (130-200 mM NaCl in Fig. 4), indicating
the calyculin A-insensitive phosphatase activity to elute at 110-130
mM NaCl. The calyculin A-sensitive fractions contain PP1
and/or 2A by Western blotting with anti-PP1 (data not shown). The
calyculin A-insensitive activity was further purified using
phenyl-Sepharose HP column chromatography. Phosphatase activity eluted
at ionic strengths corresponding to 750-550 mM NaCl (Fig. 5A). Sodium chloride was used
instead of ammonium sulfate, because ammonium sulfate negatively
affected the phosphatase assay. Peak fractions were pooled and
chromatographed on a protamine-agarose column (Fig. 5B), and
fractions containing phosphatase were pooled again, diluted 1:4 with 10 mM Tris-HCl, pH7.2, and affinity purified on a
KYKcpTLR affinity matrix. The phosphonopeptide
KYKcpTLR is similar to KYKpTLR but contains a
nonhydrolyzable phosphate mimetic instead of the phosphate group (30).
The diluted sample was adsorbed and eluted after washing with
equilibrating buffer with a linear gradient of 0-500 mM
NaCl. A major peak of activity eluted at 130-200 mM NaCl
(Fig. 5C). Peak fractions from each purification step were
analyzed on 12% SDS-polyacrylamide gels. As shown in Fig.
6, this multi-step procedure resulted in
the isolation of a 53-kDa protein that was obtained by 1130-fold
purification with a yield of 4.7% (Table
I).
Characterization of the Purified Protein-threonine
Phosphatase--
To ascertain that the 53-kDa polypeptide was in fact
the protein-threonine phosphatase activity, an aliquot of the purified preparation was subjected to Superose 12 gel permeation chromatography. A single major peak was associated with phosphatase activity, and this
peak of activity again yielded the 53-kDa band on silver-stained 12%
SDS-polyacrylamide gels (data not shown). Enzyme activity eluted as a
single peak near fractions where BSA (67-kDa) eluted in separate runs,
indicating that the purified enzyme chromatographically behaved as a
monomeric protein (data not shown).
Dephosphorylation of isolated phospho-moesin was catalyzed by the
isolated phosphatase and was complete by 30 min (Fig.
7). The purified enzyme thus has a
specific activity (Vmax) for purified platelet
phospho-moesin of 0.83 µmol/mg of protein/min and a
Km value of 0.74 µM (Table
II). The pH dependence of the enzymatic activity was relatively broad and ranged from 6.5 to 8.0. p-NPP, a substrate for many serine/threonine and tyrosine
protein phosphatases, was not a substrate for the isolated phosphatase
when assayed at several pH values (data not shown).
Purified Phosphatase Inactivates F-actin Binding of Moesin--
To
determine whether the purified phosphatase is able to alter the F-actin
binding activity of phosphorylated moesin (20), this was examined by
actin co-sedimentation. When mixed with F-actin, a large fraction of
purified platelet phospho-moesin, but only a small fraction of
nonphospho-moesin co-pelleted with actin filaments. Partial
dephosphorylation with the purified enzyme reduced the fraction of
moesin co-sedimenting with actin by about 40%, and the
dephosphorylated molecules were recovered in the supernatant fraction
(Fig. 8).
Identification of the Calyculin A-insensitive Platelet Phosphatase
as Type 2C--
Serine/threonine protein phosphatases are classified
based on their biochemical characteristics, divalent cation
requirements, and sensitivity to inhibitors. According to this
classification the purified enzyme is a type 2C protein phosphatase
(Table II). This was confirmed by Western blotting with specific
antibodies to PP2C and PP2C Our initial observations on the Thr558 phosphorylation
of moesin in resting and thrombin-activated human platelets (17) led us
to search for kinases and phosphatases that regulate modification at
this unique site. To detect and to monitor purification of potential
moesin-specific enzymes, we developed nonradioactive assays in which
phosphorylation by protein kinases or dephosphorylation by phosphatases
of synthetic peptide substrates are measured with phosphorylation
state-specific antibodies (18). These methods also proved to be quite
useful to study enzyme kinetics and to screen for potential inhibitors.
Synthetic peptides containing amino acid sequences centered around
phosphorylation or dephosphorylation sites have been used as
immobilized ligands for the purification of kinases or phosphatases (31, 32). Hydrolytically stable thiophosphorylated peptides are
particularly useful for the isolation of phosphatases (31). Because
such peptides are prepared by kinase-phosphorylation with ATP We purified and identified a type 2C protein phosphatase as one of at
least two moesin phosphatases in human platelets. PP2C is one of four
major protein serine/threonine protein phosphatases (PP1, 2A, 2B, and
2C) in eukaryotic cells and is distinct from the other three classes of
phosphatases, because it is Mg2+ or
Mn2+-dependent, because it is calyculin A- and
okadaic acid-insensitive, because it consists only of a catalytic
subunit, and because its amino acid sequence is unrelated to the
catalytic subunits of other types of phosphatases (34). The PP2C family
consist of multiple isoforms including PP2C Calyculin A treatment of platelets induces complete and okadaic acid
induces partial phosphorylation of moesin in micromolar concentrations
(17). This pattern is most consistent with a type 1 protein
phosphatase. In fact, PP1 myosin phosphatase is expressed in human
platelets and is able to dephosphorylate recombinant C-terminal and
full-length moesin in vitro. It is a serine/threonine phosphatase composed of a 38-kDa catalytic subunit PP1 We could also demonstrate that dephosphorylation of moesin with PP2C
inactivates F-actin binding. It has been proposed that F-actin binding
is regulated by an allosteric mechanism that involves, at least in
part, phosphorylation of Thr558 (20, 21). PP2C could play a
role in regulating phosphorylation at this site, because the
physiological concentration of Mg2+ is about 10 mM. It needs to be clarified, however, how addition of
calyculin A to platelets induces complete phosphorylation of moesin. A
possible candidate is certainly PP1. This enzyme is sensitive to
calyculin A, and the myosin-binding subunit interacts with moesin (13).
On the other hand, PP2C activity may be modulated by phosphorylation
(44) or through association with proteins or lipids via signaling
pathways that are affected by calyculin A. This drug also causes major
rearrangements of cytoskeletal proteins, including moesin, in the
platelet (17, 20), which could certainly compromise physiological
relationships at the plasma membrane.
The detection and purification methods described here are unique and
appear to be specific for the identification of phosphatases. They are
applicable to the identification of specific moesin kinases among the
14 distinct threonine/serine kinases that have been found in platelets
(45) and for their characterization in other cell systems. The methods
can be adapted to other phosphorylated peptides and, together with
recent progress in two-dimensional gel electrophoresis and mass
spectroscopic analysis, will provide powerful tools for the
identification of phosphorylation sites and facilitate future
functional studies (46, 47).
and PP2C
, efficiently dephosphorylate(s) highly purified platelet phospho-moesin. This reverses the activating effect of phosphorylation, and moesin no longer
co-sediments with actin filaments. In vivo, regulation of
these phosphatase activities are likely to influence dynamic interactions between the actin cytoskeleton and membrane constituents linked to moesin.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
also phosphorylates Thr558 as one site of moesin in
vitro, but it remains to be established how phosphorylation is
regulated in blood cells, in which this enzyme is predominantly
expressed (20). With regard to phosphatases, in vitro
phosphorylated moesin has been dephosphorylated with myosin
phosphatase, a calyculin A-sensitive enzyme (13).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
(rrPP2C
) and
PP2C
(rrPP2C
), and rabbit polyclonal rrPP2C
and rrPP2C
antibodies were prepared as described previously (23, 24). Actin was
prepared from rabbit skeletal muscle and polymerized (25). Calyculin A,
okadaic acid, and mycrocystin-LR were purchased from Wako Pure Chemical
Industries (Osaka, Japan). Phenyl-Sepharose HP and Superose 12 (1.0 × 300 mm) were obtained from Amersham Pharmacia Biotech.
DEAE-cellulose (DE52) was purchased from Whatman. Protamine-agarose was
purchased from Sigma.
-phosphono-valine, nonhydrolyzable phosphothreonyl mimetic, the
so-called C-P compound) affinity column was prepared as follows. The
peptide, Cys-Lys555-Tyr-Lys-cpThr-Leu-Arg560)
was chemically synthesized by Peptide Company (Osaka, Japan). The
synthetic peptide (1 mg/ml of gel) was coupled to SulfoLink Coupling
Gel (6% cross-linked beaded agarose; Pierce) according to the
procedure recommended by the manufacturer.
-mercaptoethanol, 2 mM MnCl2) the
phosphatase assay was started by adding 10 µl of enzyme preparation
and incubation for 30 min at 30 °C. Wells were washed three times
with TTBS, incubated with pAbKYKpTLR in TTBS containing 3%
BSA for 1 h, washed three times with TTBS, incubated with
anti-rabbit IgG-horseradish peroxidase conjugate in TTBS containing 3%
BSA for 1 h, and washed again three times with TTBS. Finally,
peroxidase was assayed with 0.01 mg/ml 3',3',5',5'-tetramethylbenzidine
and 0.01% H2O2 in a buffer of 0.1 M sodium acetate (pH 6.0). After addition of an equal
volume of 1 M H2SO4, the optical
density 450 nm was determined. In some experiments, pAbKYKTLR was used
instead of pAbKYKpTLR.
-mercaptoethanol, 5 mM MgCl2) and enzyme. Reaction at 30 °C was
initiated by the addition of phospho-moesin (final concentration, 50 µg/ml = 750 nM) and terminated with equal volume of
2× SDS sample buffer (125 mM Tris-HCl, 4% SDS, 20%
glycerol, 10% 2-mercaptoethanol, pH 6.8) followed by boiling for 5 min. A control incubation was performed without enzyme. The sample (500 ng of moesin) was separated by SDS-PAGE on a 9.0% polyacrylamide gel
run under reducing conditions. The stoichiometry of moesin dephosphorylation was determined from densitometric data of Western blots obtained with affinity purified pAbKYKpTLR antibodies and the enhanced chemiluminescence detection system (Amersham Pharmacia
Biotech). The phosphatase activity was calculated from the decrease in
the phosphorylation level of moesin. One unit of phosphatase activity
is the amount of enzyme that catalyzes the release of 1 nmol
phosphate/min from phospho-moesin in the standard assay. In some assays
20 mM sodium acetate/acetic acid, 20 mM MES, 20 mM Tris-HCl, or 20 mM glycine/NaOH was used as
the reaction buffer to obtain appropriate pH conditions.
-mercaptoethanol in this
assays, protein concentrations were also determined by densitometric
analysis of silver-stained SDS-polyacrylamide gels.
-mercaptoethanol, 2% glycerol), and developed with a 640-ml
linear gradient of 0-0.5 M NaCl in the equilibrating buffer at a flow rate of 1 ml/min. Fractions containing phosphatase activity were pooled.
85 °C.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (16K):
[in a new window]
Fig. 1.
Moesin phosphatase activities in platelet
lysates determined by ELISA with phosphorylation state-specific
antibodies. Microtiter plate wells were coated with synthetic
peptides coupled to bovine serum albumin KYKTLR (lanes 1 and
1') and KYKpTLR (lanes 2-4 and
2'-4'). These served simultaneously as
substrates for modification and as antigens for detection. Platelet
lysates were added in the absence (lanes 3 and
3') or presence (lanes 4 and 4') of 10 mM sodium pyrophosphate and incubated for 30 min at
30 °C. Dephosphorylation was detected with pAbKYKpTLR
(A) and pAbKYKTLR (B) as described under
"Experimental Procedures." The data represent the means ± S.D. of three separate determinations. The assay measures
dephosphorylation of the synthetic peptide in two ways (cf. lanes
3 and 4 in A and lanes 3' with
4' in B).

View larger version (18K):
[in a new window]
Fig. 2.
Magnesium ions block the effect of
phosphatase inhibitors. A, resting platelets were lysed
with Triton X-100 in the presence or absence (none) of 0.1 mM EDTA. BSA-KYKpTLR-coated wells were incubated
with the lysate in the presence of phosphatase inhibitors (10 mM sodium pyrophosphate (PPi) or 100 nM calyculin A (CA)) and/or 10 mM
magnesium chloride for the indicated time periods at 30 °C.
B, resting platelets remained untreated (white
bars, dimethyl sulfoxide vehicle) or were pretreated with 1 µM calyculin A (black bars) for 10 min at
37 °C before lysis with Triton X-100. BSA-KYKpTLR-coated
wells were incubated with the lysate for 10 min at 30 °C
(lanes 1 and 2, 1 µM calyculin A;
lanes 3 and 4, 10 mM
MgCl2; lanes 5 and 6, 1 µM calyculin A and 10 mM MgCl2).
Dephosphorylation was detected with pAbKYKpTLR. The data
represent the means ± S.D. of three separate
determinations.

View larger version (20K):
[in a new window]
Fig. 3.
Recovery of phosphatases in detergent
extracts of platelet. Phosphatase activities were measured in the
presence or absence of 100 nM calyculin A using
BSA-KYKpTLR as the substrate. The data represent the
means ± S.D. of three separate determinations. A,
aliquots of Triton X-100 extract of the insoluble fraction (membrane,
white bars), and soluble fraction (cytosol, black
bars) from resting platelets were tested and both contained
calyculin-sensitive and -insensitive activity. B, Triton
X-100 extracts (membrane, white bars) and NaCl extracts
(cytoskeleton, black bars) were obtained from human
platelets before and after thrombin activation. Thrombin stimulation
does not appreciably change phosphatase activity in either
fraction.

View larger version (21K):
[in a new window]
Fig. 4.
Separation of calyculin A-sensitive and
-insensitive phosphatase activities by column chromatography on
DEAE-cellulose. Membrane extracts from resting platelets were
separated by column chromatography on DEAE-cellulose (DE52). Absorbance
at 280 nm is shown by the dotted line, and the concentration
of NaCl is shown by the solid diagonal line. The relative
phosphatase activity in individual column fractions, measured by the
ELISA procedure in the absence or presence of calyculin A, is plotted.
, total activity;
, calyculin A-insensitive; ×, calyculin
A-sensitive. The bar on top of the figure
indicates the pooled fractions used for the next purification
step.

View larger version (19K):
[in a new window]
Fig. 5.
Multiple steps of purification of the
calyculin A-insensitive phosphatase activity. A,
phenyl-Sepharose; B, protamine-agarose; C,
KYKcpTLR affinity column. cpT, phosphonic acid
threonine. Enzyme activities were assayed using KYKpTLR as a
substrate by ELISA and are plotted as relative activity (solid
line). Absorbance at 280 nm is shown by the dotted
lines, and the concentration of NaCl is shown by the solid
diagonal lines. Bars indicate the fractions
pooled.

View larger version (72K):
[in a new window]
Fig. 6.
SDS-polyacrylamide gel electrophoresis of
protein samples of each purification step. Aliquots of each step
of the purification were subjected to 12% SDS-polyacrylamide gel
electrophoresis, and the gel was silver-stained. T, Triton
X-100 extract from human platelets; E, ethanol precipitate;
DE, DE52 pool; PH, phenyl-Sepharose HP pool;
PR, protamine-agarose pool; PA,
KYKcpTLR-affinity column pool. The molecular mass of
standard proteins is indicated on the left.
Purification of the protein threonine phosphatase

View larger version (24K):
[in a new window]
Fig. 7.
The purified enzyme dephosphorylates purified
platelet phospho-moesin. Equal amounts of phosphorylated platelet
moesin were incubated with aliquots of the purified protein-threonine
phosphatase for the designated time periods. SDS sample buffer was
added to stop the reaction. Aliquots of the mixture (500 ng of moesin)
was separated by SDS-PAGE on a 9.0% polyacrylamide gel. Phosphorylated
moesin was detected by immunoblotting using pAbKYKpTLR and
the enhanced chemiluminescence detection system. The antibodies were
removed from the membrane according to the manufacturer's protocol.
Moesin was then detected by immunoblotting with monoclonal antibodies
(mAbMo) and enhanced chemiluminescence detection. Note
complete dephosphorylation of full-length moesin in 30 min.
Properties of moesin phosphatase

View larger version (23K):
[in a new window]
Fig. 8.
Purified platelet phospho-moesin loses
F-actin binding activity after treatment with the purified
phosphatase. Purified phosphorylated (p-moesin) and
nonphosphorylated (np-moesin) platelet moesin (0.3 µM) were incubated either each alone or together with
purified enzyme for 30 min at 25 °C. The mixture was incubated with
phalloidin-stabilized F-actin (2 µM) in buffer F for 20 min at 25 °C prior to centrifugation as described under
"Experimental Procedures." Equal volumes of supernatant
(S) and pellet (P) fractions were analyzed by
SDS-PAGE. Moesin (anti-moesin) and phosphorylated moesin
(anti-KYKpTLR) were detected by immunoblotting. A typical
result from three independent experiments is shown. Note the decrease
in pelleted moesin in the phosphatase-treated sample as compared with
untreated p-moesin and increased recovery in the supernatant.
(Fig. 9).
We were unable to test whether the enzyme preparation also contains
PP2C
, because human-specific antibodies are not available. Both
recombinant PP2C
and PP2C
, but neither alkaline nor acid
phosphatase, are able to dephosphorylate phospho-moesin (Fig.
10) and to inactivate F-actin binding
(data not shown).

View larger version (47K):
[in a new window]
Fig. 9.
Immunological identification of purified
enzyme as type 2C protein phosphatase. Human platelets lysate,
purified enzyme, recombinant mouse PP2C
, and recombinant mouse
PP2C
were subjected to immunoblotting with PP2C (A),
PP2C
(B), and PP1(FL-18) (C) polyclonal
antibodies.

View larger version (62K):
[in a new window]
Fig. 10.
Specific dephosphorylation of purified
phospho-moesin by recombinant PP2C
and
PP2C
. Purified phospho-moesin was
incubated with recombinant PP2C
(rec. PP2C
), PP2C
(rec. PP2C
), alkaline phosphatase (AlkP) from
calf intestine or E. coli, or acid phosphatase
(AcidP) from wheat germ for 60 min at 30 °C. The reaction
was stopped with 2× SDS sample buffer and analyzed by SDS-PAGE.
Proteins were stained with Coomassie Brilliant Blue (CBB).
Dephosphorylation is detected by immunoblotting with
pAbKYKpTLR.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
S, the
application depends on whether a particular kinase is available or not.
As an alternative, the phosphonic acid mimetic, the so-called C-P
compound, can be chemically synthesized and is nonhydrolyzable (33).
Moesin kinases were unknown at the time when we started to purify
moesin phosphatases from platelets, and we therefore employed the
synthetic phosphonic acid peptide, KYKcpTLR as the affinity
ligand for purification. cpT is
-phosphono-valine or a
phosphothreonyl mimetic.
(34), PP2C
(
-1,
-2, -3, -4, and -5) (35), PP2C
(36), Wip1 (37), and FIN13 (38) in
mammals. Although little is known of their physiological role, they
appear to function in Ca2+-dependent signal
transduction (39), DNA repair systems (40), mitogen-activated protein
kinase systems (41), and the dephosphorylation of cofilin (42).
, a 130-kDa myosin-binding subunit, and a 20-kDa subunit (43). The calyculin A-sensitive phosphatase that we have detected by Western blotting in
chromatographic fractions could thus be identical to myosin phosphatase. However, this would require further analysis, because substrate specific properties have not been firmly established. For
example, Fukata et al. (13) phosphorylated recombinant
C-terminal and full-length moesin with Rho-kinase in vitro
but did not determine phosphorylation sites and stoichiometry. Matsui
et al. (19) showed that this enzyme phosphorylated ~100%
of Thr564 (corresponding to Thr558 of moesin)
of a recombinant radixin C-terminal domain fragment and with ~40%
efficiency an additional site. These could be dephosphorylated with
alkaline phosphatase (19), whereas we could not remove the phosphate
from the single physiologically relevant site of highly purified
full-length platelet phospho-moesin under similar experimental
conditions, as shown here.
| |
ACKNOWLEDGEMENTS |
|---|
We are grateful to Dr. Heinz Furthmayr (Stanford University) for critically reading the manuscript and for valuable suggestions. We also thank Miyagi Red Cross Blood Center (Sendai, Japan) for providing platelets.
| |
FOOTNOTES |
|---|
* This work was supported in part by the Naito Foundation, by the Nissan Science Foundation, and by a grant-in-aid for science research from the Ministry of Education, Science and Culture of Japan (to F. N.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ These authors contributed equally to this work.
To whom correspondence should be addressed: Lab. of
Environmental Biochemistry, Dept. of Environmental Biology, Graduate
School of Agricultural Science, Tohoku University, Sendai 981-8555, Japan. Tel./Fax: 81-22-717-8837; E-mail:
fnaka@bios.tohoku.ac.jp.
| |
ABBREVIATIONS |
|---|
The abbreviations used are:
PP1, protein
phosphatase type 1;
PP2C, protein phosphatase type 2C;
BSA, bovine
serum albumin;
phospho-moesin, phosphorylated moesin;
ELISA, enzyme-linked immosorbent assay;
rr, recombinant rat;
PAGE, polyacrylamide gel electrophoresis;
MES, 2-(N-morpholino)ethanesulfonic acid;
ATP
S, adinosine
5'-O-(thiotriphosphate).
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Amieva, M. R., and Furthmayr, H. (1995) Exp. Cell Res. 219, 180-196[CrossRef][Medline] [Order article via Infotrieve] |
| 2. | Berryman, M., Franck, Z., and Bretscher, A. (1993) J. Cell Sci. 105, 1025-1043[Abstract] |
| 3. |
Sato, N.,
Yonemura, S.,
Obinata, T.,
Tsukita, S.,
and Tsukita, S.
(1991)
J. Cell Biol.
113,
321-330 |
| 4. | Niggli, V., Andreoli, C., Roy, C., and Mangeat, P. (1995) FEBS Lett. 376, 172-176[CrossRef][Medline] [Order article via Infotrieve] |
| 5. |
Serrador, J. M.,
Nieto, M.,
Alonso-Lebrero, J. L.,
del Pozo, M. A.,
Calvo, J.,
Furthmayr, H.,
Schwartz-Albiez, R.,
Lozano, F.,
Gonzalez-Amaro, R.,
Sanchez-Mateos, P.,
and Sanchez-Madrid, F.
(1998)
Blood
91,
4632-4644 |
| 6. |
Tsukita, S.,
Oishi, K.,
Sato, N.,
Sagara, J.,
Kawai, A.,
and Tsukita, S.
(1994)
J. Cell Biol.
126,
391-401 |
| 7. |
Serrador, J. M.,
Alonso-Lebrero, J. L.,
del Pozo, M. A.,
Furthmayr, H.,
Schwartz-Albiez, R.,
Calvo, J.,
Lozano, F.,
and Sanchez-Madrid, F.
(1997)
J. Cell Biol.
138,
1409-1423 |
| 8. | Helander, T. S., Carpen, O., Turunen, O., Kovanen, P. E., Vaheri, A., and Timonen, T. (1996) Nature 382, 265-268[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Yonemura, S.,
Hirao, M.,
Doi, Y.,
Takahashi, N.,
Kondo, T.,
Tsukita, S.,
and Tsukita, S.
(1998)
J. Cell Biol.
140,
885-895 |
| 10. |
Takahashi, K.,
Sasaki, T.,
Mammoto, A.,
Takaishi, K.,
Kameyama, T.,
Tsukita, S.,
Tsukita, S.,
and Takai, Y.
(1997)
J. Biol. Chem.
272,
23371-23375 |
| 11. |
Reczek, D.,
Berryman, M.,
and Bretscher, A.
(1997)
J. Cell Biol.
139,
169-179 |
| 12. | Dransfield, D. T., Bradford, A. J., Smith, J., Martin, M., Roy, C., Mangeat, P. H., and Goldenring, J. R. (1997) EMBO J. 16, 35-43[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Fukata, Y.,
Kimura, K.,
Oshiro, N.,
Saya, H.,
Matsuura, Y.,
and Kaibuchi, K.
(1998)
J. Cell Biol.
141,
409-418 |
| 14. |
Murthy, A.,
Gonzalez-Agosti, C.,
Cordero, E.,
Pinney, D.,
Candia, C.,
Solomon, F.,
Gusella, J.,
and Ramesh, V.
(1998)
J. Biol. Chem.
273,
1273-1276 |
| 15. | Takahashi, K., Sasaki, T., Mammoto, A., Hotta, I., Takaishi, K., Imamura, H., Nakano, K., Kodama, A., and Takai, Y. (1998) Oncogene 16, 3279-3284[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Pestonjamasp, K., Amieva, M. R., Strassel, C. P., Nauseef, W. M., Furthmayr, H., and Luna, E. J. (1995) Mol. Biol. Cell 6, 247-259[Abstract] |
| 17. |
Nakamura, F.,
Amieva, M. R.,
and Furthmayr, H.
(1995)
J. Biol. Chem.
270,
31377-31385 |
| 18. | Nakamura, F., Amieva, M. R., Hirota, C., Mizuno, Y., and Furthmayr, H. (1996) Biochem. Biophys. Res. Commun. 226, 650-656[CrossRef][Medline] [Order article via Infotrieve] |
| 19. |
Matsui, T.,
Maeda, M.,
Doi, Y.,
Yonemura, S.,
Amano, M.,
Kaibuchi, K.,
Tsukita, S.,
and Tsukita, S.
(1998)
J. Cell Biol.
140,
647-657 |
| 20. |
Nakamura, F.,
Huang, L.,
Pestonjamasp, K.,
Luna, E.,
and Furthmayr, H.
(1999)
Mol. Biol. Cell
10,
2669-2685 |
| 21. |
Huang, L.,
Wong, T. Y. W.,
Lin, R. C. C.,
and Furthmayr, H.
(1999)
J. Biol. Chem.
274,
12803-12810 |
| 22. | Tsukita, S., Yonemura, S., and Tsukita, S. (1997) Trends Biochem. Sci. 22, 53-58[CrossRef][Medline] [Order article via Infotrieve] |
| 23. | Terasawa, T., Kobayashi, T., Murakami, T., Ohnishi, M., Kato, S., Tanaka, O., Kondo, H., Yamamoto, H., Takeuchi, T., and Tamura, S. (1993) Arch. Biochem. Biophys. 307, 342-349[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Kato, S., Kobayashi, T., Kusuda, K., Nishina, Y., Nishimune, Y., Yomogida, K., Yamamoto, M., Sakagami, H., Kondo, H., Ohnishi, M., Chida, N., Yanagawa, Y., and Tamura, S. (1996) FEBS Lett. 396, 293-297[CrossRef][Medline] [Order article via Infotrieve] |
| 25. |
Spudich, J. A.,
and Watt, S.
(1971)
J. Biol. Chem.
246,
4866-4871 |
| 26. |
Kouns, W. C.,
Fox, C. F.,
Lamoreaux, W. J.,
Coons, L. B.,
and Jennings, L. K.
(1991)
J. Biol. Chem.
266,
13891-13900 |
| 27. | Erdodi, F., Csortos, C., Sparks, L., Muranyi, A., and Gergely, P. (1992) Arch. Biochem. Biophys. 298, 682-687[CrossRef][Medline] [Order article via Infotrieve] |
| 28. | Waymack, P. P., and Van Etten, R. L. (1991) Arch. Biochem. Biophys. 288, 621-633[CrossRef][Medline] [Order article via Infotrieve] |
| 29. |
Woscholski, R.,
Waterfield, M. D.,
and Parker, P. J.
(1995)
J. Biol. Chem.
270,
31001-31007 |
| 30. | Landt, M., Boltz, S. C., and Butler, L. G. (1978) Biochemistry 17, 915-919[CrossRef][Medline] [Order article via Infotrieve] |
| 31. | McGowan, C. H., and Cohen, P. (1987) Eur. J. Biochem. 166, 713-721[Medline] [Order article via Infotrieve] |
| 32. | Woodgett, J. R. (1989) Anal. Biochem. 180, 237-241[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Dissing, J., Dahl, O., and Svensmark, O. (1979) Biochim. Biophys. Acta 569, 159-176[Medline] [Order article via Infotrieve] |
| 34. |
Tamura, S.,
Lynch, K. R.,
Larner, J.,
Fox, J.,
Yasui, A.,
Kikuchi, K.,
Suzuki, Y.,
and Tsuiki, S.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
1796-1800 |
| 35. | Kato, S., Terasawa, T., Kobayashi, T., Ohnishi, M., Sasahara, Y., Kusuda, K., Yanagawa, Y., Hiraga, A., Matsui, Y., and Tamura, S. (1995) Arch. Biochem. Biophys. 318, 387-393[CrossRef][Medline] [Order article via Infotrieve] |
| 36. | Travis, S. M., and Welsh, M. J. (1997) FEBS Lett. 412, 415-419[CrossRef][Medline] [Order article via Infotrieve] |
| 37. |
Fiscella, M.,
Zhang, H.,
Fan, S.,
Sakaguchi, K.,
Shen, S.,
Mercer, W. E.,
Vande Woude, G. F.,
O'Connor, P. M.,
and Appella, E.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
6048-6053 |
| 38. | Guthridge, M. A., Bellosta, P., Tavoloni, N., and Basilico, C. (1997) Mol. Cell. Biol. 17, 5485-5498[Abstract] |
| 39. |
Fukunaga, K.,
Kobayashi, T.,
Tamura, S.,
and Miyamoto, E.
(1993)
J. Biol. Chem.
268,
133-137 |
| 40. | Kobayashi, T., Yasui, A., Ohnishi, M., Kato, S., Sasahara, Y., Kusuda, K., Chida, N., Yanagawa, Y., Hiraga, A., and Tamura, S. (1996) Mut. Res. 362, 213-217[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Shiozaki, K., and Russell, P. (1995) EMBO J. 14, 492-502[Medline] [Order article via Infotrieve] |
| 42. |
Takuma, T.,
Ichida, T.,
Yokoyama, N.,
Tamura, S.,
and Obinata, T.
(1996)
J. Biochem. (Tokyo)
120,
35-41 |
| 43. |
Nakai, K.,
Suzuki, Y.,
Kihira, H.,
Wada, H.,
Fujioka, M.,
Ito, M.,
Nakano, T.,
Kaibuchi, K.,
Shiku, H.,
and Nishikawa, M.
(1997)
Blood
90,
3936-3942 |
| 44. | Kobayashi, T., Sadaie, M., Ohnishi, M., Wang, H., Ikeda, S., Hanada, M., Yanagawa, Y., Nakajima, T., and Tamura, S. (1998) Biochem. Biophys. Res. Commun. 251, 296-300[CrossRef][Medline] [Order article via Infotrieve] |
| 45. |
Ferrell, J. E., Jr.,
and Martin, G. S.
(1989)
J. Biol. Chem.
264,
20723-20729 |
| 46. | Yan, J. X., Packer, N. H., Gooley, A. A., and Williams, K. L. (1998) J. Chromatogr. A 808, 23-41[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Packer, N. H., Pawlak, A., Kett, W. C., Gooley, A. A., Redmond, J. W., and Williams, K. L. (1997) Electrophoresis 18, 452-460[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
L. Zhu, R. Zhou, S. Mettler, T. Wu, A. Abbas, J. Delaney, and J. G. Forte High turnover of ezrin T567 phosphorylation: conformation, activity, and cellular function Am J Physiol Cell Physiol, September 1, 2007; 293(3): C874 - C884. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhou, L. Zhu, A. Kodani, P. Hauser, X. Yao, and J. G. Forte Phosphorylation of ezrin on threonine 567 produces a change in secretory phenotype and repolarizes the gastric parietal cell J. Cell Sci., October 1, 2005; 118(19): 4381 - 4391. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Zhou, X. Cao, C. Watson, Y. Miao, Z. Guo, J. G. Forte, and X. Yao Characterization of Protein Kinase A-mediated Phosphorylation of Ezrin in Gastric Parietal Cell Activation J. Biol. Chem., September 12, 2003; 278(37): 35651 - 35659. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ofek, D. Ben-Meir, Z. Kariv-Inbal, M. Oren, and S. Lavi Cell Cycle Regulation and p53 Activation by Protein Phosphatase 2Calpha J. Biol. Chem., April 11, 2003; 278(16): 14299 - 14305. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Piekny, A. Wissmann, and P. E. Mains Embryonic Morphogenesis in Caenorhabditis elegans Integrates the Activity of LET-502 Rho-Binding Kinase, MEL-11 Myosin Phosphatase, DAF-2 Insulin Receptor and FEM-2 PP2c Phosphatase Genetics, December 1, 2000; 156(4): 1671 - 1689. [Abstract] [Full Text] |
||||
![]() |
A. Cheng, P. Kaldis, and M. J. Solomon Dephosphorylation of Human Cyclin-dependent Kinases by Protein Phosphatase Type 2Calpha and beta 2 Isoforms J. Biol. Chem., October 27, 2000; 275(44): 34744 - 34749. [Abstract] [Full Text] [PDF] |